Alchemy Capital’s Deputy CIO Alok Agarwal outlines the sectors and market segments he sees offering opportunities as valuations reset and earnings growth broadens.

Why hasn't the Nifty really become cheap despite giving no returns in the last two years? Were we that overvalued in September 2024?

The Nifty has underperformed several pockets of the broader market this year, while many mid- and small-cap companies have continued to deliver earnings growth. Is this structural broadening or a late-cycle rotation?

FPIs have again turned sellers, with rising global bond yields, a weaker rupee, elevated crude prices and geopolitical risks affecting flows. What needs to change for foreign investors to return meaningfully?

What are your expectations from Q2FY27 earnings? Some think trouble could begin Q3 onwards as the high base effect kicks in.

The AI investment cycle is creating demand for power, cooling, transmission, equipment and data-centre infrastructure. Where are the most investible opportunities?

Is India likely to emerge primarily as a data-centre destination, a supplier to the global AI infrastructure ecosystem, or both?

Within healthcare, where do you see the best medium-term risk-reward: hospitals, domestic pharma, CDMO, diagnostics or medical devices?

Defence has become a major structural theme, but valuations are demanding. Is this a bad time to start picking defence stocks?

What percentage of a long-term equity portfolio should reasonably be allocated to midcaps and smallcaps, given the possibility of a sharp drawdown?